Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowFresh off the opening of its $200 million-plus headquarters downtown, Elanco Animal Health on Wednesday posted double-digit revenue growth for the third quarter, driven by blockbusters such as its Credelio Quattro chewables for dogs to prevent parasites such as fleas, ticks and heartworms.
For the quarter, Elanco reported revenue of $1.14 billion, up 10% from a year ago, and earnings of 19 cents a share when adjusted for one-time events, well above the 13 cents analysts were expecting, according to Zacks.
The company also raised its full-year 2025 revenue estimate to $4.65 billion to $4.67 billion, also above the $4.6 billion analysts were expecting.
Despite the growth, the Indianapolis-based company reported a loss of $34 million for the third quarter as it continues with write-downs and financial adjustments from past moves such as its $6.9 billion acquisition of Bayer Animal Health. Elanco CEO Jeff Simmons told IBJ that the loss “takes into account all of the acquisition cost, all of the debt cost.”
Simmons said the company’s results from ongoing operations demonstrate its ongoing momentum and turnaround.
“It’s all back to the consistent, reliable delivery and a long runway of shareholder value,” he said. “We will lead the animal health sector in growth this quarter.

“This is the highest quality of growth that I have seen in the company in more than three years … We are opening the door truly to the next era of growth and innovation.”
Shares of Elanco were up about 3% in pre-marketing trading Wednesday, but dropped after the opening bell, posting a loss of about 2.5%, down to about $21.94, by midmorning.
Beyond the performance of its blockbuster pet parasite drug Credelio Quattro, Elanco also highlighted the growth of Zenrelia, its treatment for itching and allergies in dogs. The company’s farm animal category, Experior, which reduces ammonia gas in cattle, saw quarterly sales up about 70% year-over-year.
Overall, Elanco’s pet health unit posted revenue of $533 million, an increase of 10%. Its farm animal business revenue was $593 million, up 12%.
Simmons added that Elanco employees have embraced their new modern headquarters on the west side of downtown.
“I’m looking at a ‘parking garage full’ sign. The rooms are full,” Simmons said. “I think every aspect of making this a destination, not an obligation, is coming true; the engagement, the open workspace, the opportunity for more engagement.”
Elanco is increasing its visibility locally since relocating its headquarters from Greenfield to downtown.
The company will host the 2025 BioCrossroads Life Sciences Summit on Nov. 13 in partnership with AgriNovus Indiana. The event will highlight Indiana’s life-science sector, with speakers and panelists including Eli Lilly and Co. CEO David Ricks, Purdue University President Mung Chiang and Indiana University President Pam Whitten.
Please enable JavaScript to view this content.
Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our comment policy that will govern how comments are moderated.